Japan grants Sakigake designation to Nippon Shinyaku NS-035 for Fukuyama muscular dystrophy

• Nippon Shinyaku received Japan MHLW SAKIGAKE designation for NS-035 to treat Fukuyama congenital muscular dystrophy.
• Status supports accelerated development in Japan, including eligibility for a shortened regulatory review timeline.
• NS-035 is an antisense oligonucleotide targeting fukutin-gene mutations, aiming to restore functional protein production and slow disease progression.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nippon Shinyaku Co. Ltd. published the original content used to generate this news brief on August 26, 2026, and is solely responsible for the information contained therein.